Varda has raised $491.0M in total across 5 funding rounds.
Varda's investors include 01 Advisors, 11k Ventures, 8VC, Abstract Ventures, Afore Capital, Also Capital, Alumni Ventures, Andreessen Horowitz, Anorak Ventures, Ballistic Ventures, Bedrock Capital, Caffeinated Capital.
Varda Space Industries is a space technology company that builds autonomous spacecraft for in-space manufacturing, primarily targeting pharmaceuticals processed in microgravity and returned to Earth via reentry capsules.[1][2][4][5] It serves biopharmaceutical firms and government agencies like the US Department of Defense (DoD), solving the challenge of producing superior drug crystals and materials impossible in Earth's gravity, such as novel polymorphs for cancer, diabetes, and chronic pain treatments.[1][3][4] Varda's Winnebago Series (W-Series) capsules handle end-to-end operations—sample preparation, orbital manufacturing, and safe reentry—while also enabling hypersonic testing for military applications.[1][2] Growth includes multiple missions (W-1 in 2023, W-3 in March 2025), a DoD contract through 2028, partnerships like SSPC for crystallization models, and ~$5M in seed funding by May 2025.[1][4]
Varda Space Industries was founded in January 2021 by Will Bruey, a former SpaceX electrical engineer, and Delian Asparouhov, a Founders Fund associate, with backing from investors like Khosla Ventures, Founders Fund, Lux Capital, and General Catalyst.[2][4][5] The idea emerged from leveraging cheap access to space via reusable rockets to manufacture high-value Earth products in microgravity, starting with pharmaceuticals but expanding to hypersonics and fiber optics.[2][5] Early traction included contracts with Rocket Lab (2021) and SpaceX for launches, the first W-1 mission on Falcon 9 in June 2023 demonstrating pharmaceutical processing, and a 2025 Air Force Prometheus program for hypersonic tests.[1][4]
Varda rides the low Earth orbit (LEO) economy boom, fueled by falling launch costs from reusable rockets, enabling microgravity as an industrial tool for pharma, materials, and defense.[5][6][7] Timing aligns with surging demand for in-orbit manufacturing amid ISS retirement and private stations' rise, where Varda leads by solving reentry logistics—a key bottleneck for competitors like SpacePharma or Space Tango.[3][6] Market forces include high pharma margins, DoD hypersonic needs, and trends in zero-g R&D for semiconductors/biotech; Varda influences the ecosystem by standardizing orbital factories, accelerating commercial space infrastructure, and proving space's terrestrial ROI.[1][6][7]
Varda is positioned to scale W-Series missions, expand pharma partnerships (e.g., via SSPC models), and deepen DoD ties through 2028, potentially hitting production cadence with more launches.[1][4] Trends like LEO stations growth and microgravity demand will propel it, evolving its role from pioneer to infrastructure provider in a multi-billion orbital economy.[6][7] As reentry tech matures, Varda could unlock mass-market space manufacturing, directly benefiting Earth lives—transforming the simple vision of space as industry's next frontier into reality.[2][5]
Varda has raised $491.0M across 5 funding rounds. Most recently, it raised $190.0M Series C in July 2025.
